Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:17 AM
Ignite Modification Date:
2025-12-25 @ 1:17 AM
NCT ID:
NCT02556593
Eligibility Criteria:
Inclusion Criteria:
* Pathologically confirmed NSCLC and wild type EGFR
* 4-10 brain metastases on high quality CT scanning or MRI.
* No previous EGFR-TKI treatment.
* No previous brain radiotherapy.
* More than 4 weeks from last chemotherapy.
* Expected Survival of at least 2 months.
* KPS≥ 70
* RTOG RPA performance status 0-1
* Lab tests should meet these criteria: White blood cell count ≥3×10\^9 /L;Platelet count≥100×10\^9 /L;Total bilirubin 1.5 times or less the upper limits of normal (ULN); AST and ALT 1.5 times or less the ULN; Serum creatinine 1.5 times or less the ULN or creatinine clearance rate(CCR) greater than or equal to 60 ml/min.
* Pregnancy test (-)
* Be able to sign informed consent form.
Exclusion Criteria:
* With unstable systematical diseases (concluding acute infection, grade 4 hypertension, unstable angina pectoris, congestive heart failure, hepatopathy, nephropathy, metabolic diseases)
* With metastases on meninges.
* Taking antiepileptics (phenytoin sodium etc.) at the same time
* Unable to oral medication.
* Previous or recent another malignancy, except for nonmelanoma skin cancer or cervical cancer in situ
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT02556593
Study Brief:
Protocol Section:
NCT02556593